Maksim Labkouski
Last year around this time, several leading drugmakers announced significant M&A deals to help fill their pipelines, including Bristol-Myers Squibb’s (BMY) proposed takeovers of Karuna and RayzeBio, and AbbVie’s (ABBV) deals to buy ImmunoGen and Cerevel.
Which brings us to